Antiplatelet and anticoagulant use after myocardial infarction.
Clin Cardiol
; 19(5): 357-65, 1996 May.
Article
en En
| MEDLINE
| ID: mdl-8723593
ABSTRACT
Coronary thrombosis leading to myocardial infarction is a complex process involving the interaction of the arterial wall, the coagulation cascade, and platelets. Increased understanding of the molecular biology of thrombosis has prompted an evolution in antithrombotic therapy, from the early use of warfarin following myocardial infarction to agents targeting specific receptors or modulators in the thrombotic process. The complexity of thrombosis allows for numerous sites of pharmacologic intervention; the multiple pathways leading to platelet aggregation and thrombin formation provide the opportunity for combined therapies. This review presents the current clinical data on antiplatelet, anticoagulant, and specific antithrombin therapies following myocardial infarction.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Trombosis Coronaria
/
Inhibidores de Agregación Plaquetaria
/
Anticoagulantes
/
Infarto del Miocardio
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Clin Cardiol
Año:
1996
Tipo del documento:
Article
País de afiliación:
Estados Unidos